DOI: 10.1055/s-00000054

Pharmacopsychiatry

Issue 02 · Volume 25 · March 1992 DOI: 10.1055/s-002-10089

Preface

63
Maitre, L.: 17th Symposium of AGNP, Nuremberg 1991

64
Müller-Spahn, F.; Oswald, W. D.; Heuser, I.; Hoyer, S.; Leenders, K. L.; Stoppe, G.: Dementia - New Aspects in Early Diagnosis
65
Schlegel, S.: Receptor Mapping by Single Photon Emission Computerized Tomography in Relation to Clinical Aspects and Pharmacopsychiatry
66
Strauss, W. H.; Klieser, E.: Combination of Pharmacotherapy and Psychotherapy/Advantage or Disadvantage
67
Linden, M.: Epidemiological Methods in the Evaluation of Drugs, Field Studies in the Postmarketing Phase
68
Steiger, A.: Ligands of the GABA-Benzodiazepine-Receptor-Complex - Recent Clinical and Neurobiological Research
69
Kissling, W.; Fleischhacker, W. W.: Optimising Prophylactic Treatment of Schizophrenia by Means of Treatment Standards and Compliance Improvement
71
Gaebel, W.; Ellgring, H.: Experimental Psychopathology in Biological Psychiatry and Psychopharmacology
72
Hiemke, C.: Drug Monitoring in Psychiatric Patients:Which Approach is Userul to ImprovePsychopharmacotherapy?
74
Fleischhacker, W. W.: Clozapine - Beneficial and Untoward Effects: An Update
75
Möller, H. J.; Helmchen, H.: Organisatory and Ethical Aspects of Clinical Trials
76
Albus, M.; Netter, P.: Methodological Aspects of Studies with Anxiolytics
77
Krüger, H. P.: Speech Chronemics in Drug Evaluation